Product Overview
Composition
Solution for intramuscular injection.
1 amp. contains glycosaminoglycan-peptide complex 1 ml.
pharmachologic effect
Pharmacodynamics
Combined preparation of animal origin, contains a glycosaminoglycan-peptide complex. The action of the drug is due to the combined action of its active components.
Normalizes metabolism in cartilaginous hyaline tissue: enhances the biosynthesis of sulfated mucopolysaccharides and collagen, stimulates the regeneration of articular cartilage, reduces enzyme activity and inhibits catabolic processes in cartilage tissue.
Pharmacokinetics
No studies have been conducted.
Indications
Degenerative-dystrophic diseases of the joints: gonarthrosis, arthrosis of the interdigital joints, coxarthrosis, spondylosis, spondyloarthrosis, meniscopathy, patellar chondromalacia.
Contraindications
- hypersensitivity to drug components,
- rheumatoid arthritis,
- age up to 18 years,
- pregnancy, breastfeeding period,
- use in women of reproductive age who do not follow reliable methods of contraception.
Side effects
According to WHO, unwanted effects are classified according to the frequency of their development as follows: very often (≥1 / 10), often (from ≥1 / 100 to.
From the immune system:
Rarely: allergic reactions, including anaphylactoid reactions, anaphylactic shock.
If you experience side effects that are not described in these instructions, you should stop taking the drug and inform your doctor about it.
Interaction
The drug Rumalon® can be used simultaneously with non-steroidal anti-inflammatory drugs and glucocorticosteroids.
With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, their effect may be enhanced.
How to take, course of administration and dosage
The drug is administered deeply intramuscularly: on the first day - 0.3 ml, on the second day - 0.5 ml, and then 3 times a week, 1 ml for 5-6 weeks.
A second course of treatment - after consulting a doctor according to the same scheme.
Special instructions
With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, frequent monitoring of blood coagulation indicators is necessary.
The use of the drug does not affect the ability to perform potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, the work of a dispatcher and an operator).
